Takara Holdings Inc. Stock

Equities

2531

JP3459600007

Distillers & Wineries

Market Closed - Japan Exchange 02:00:00 2024-05-31 am EDT 5-day change 1st Jan Change
1,060 JPY +0.90% Intraday chart for Takara Holdings Inc. -0.80% -14.49%
Sales 2024 339B 2.16B Sales 2025 * 388B 2.47B Capitalization 207B 1.31B
Net income 2024 16.18B 103M Net income 2025 * 17.6B 112M EV / Sales 2024 0.62 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.53 x
P/E ratio 2024
13 x
P/E ratio 2025 *
11.9 x
Employees 5,171
Yield 2024
2.71%
Yield 2025 *
2.93%
Free-Float 86.17%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.90%
1 week-0.80%
1 month+0.90%
3 months-15.21%
6 months-11.97%
Current year-14.49%
More quotes
1 week
1 039.00
Extreme 1039
1 069.00
1 month
1 039.00
Extreme 1039
1 103.00
Current year
996.10
Extreme 996.1
1 290.00
1 year
996.10
Extreme 996.1
1 324.00
3 years
918.00
Extreme 918
1 642.00
5 years
617.00
Extreme 617
1 675.00
10 years
617.00
Extreme 617
1 777.00
More quotes
Managers TitleAgeSince
President 61 85-03-31
Chairman 81 68-03-31
Director/Board Member 61 85-03-31
Members of the board TitleAgeSince
Chairman 81 68-03-31
Director/Board Member 62 85-03-31
President 61 85-03-31
More insiders
Date Price Change Volume
24-05-31 1,060 +0.90% 1,103,300
24-05-30 1,050 +0.05% 477,300
24-05-29 1,050 -1.41% 698,500
24-05-28 1,064 -0.37% 476,800
24-05-27 1,068 +0.05% 463,700

Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT

More quotes
TAKARA HOLDINGS INC. is Japan-based brewing holding company. The Company operates in three business segments. The TAKARA SHUZO CO., LTD segment is engaged in the manufacture and sales of alcohol beverages, food seasonings and other businesses. The TAKARA SHUZO INTERNATIONAL CO., LTD segment exportr liquors from Japan, manufactures and sells liquors overseas, and conducts Japanese food wholesale business. The TAKARA BIO INC segment involves in the manufacture and sale of research reagents, physical and chemical equipment, mushrooms, the provision of contract research services on gene therapy and cell therapy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings